Step Therapy: Why Your Insurance Is Making You Take a Drug You Don't Want

If your insurance company told you it will not cover your prescribed medication until you try a different one first, you've encountered step therapy. It goes by a number of names in the industry, "fail first" being the most accurate. The basic structure is this: before your plan will pay for the drug your doctor prescribed, it requires you to try and fail a less expensive drug on its preferred list.

Your physician did not ask for this requirement. The insurance company designed it.

How Step Therapy Works

Step therapy requirements are built into a plan's formulary management policies. When a doctor prescribes a drug in a step therapy sequence, the prior authorization process identifies the requirement and the claim is held until the plan determines whether the first step has been completed.

The sequence typically moves from generic or lower-cost options to more expensive branded or specialty drugs. In rheumatology, for example, a plan might require trials of one or two conventional disease-modifying agents before approving a biologic. In dermatology, topical treatments before systemics. In neurology, certain first-line agents before newer, more targeted therapies.

The required step drug is not necessarily the wrong drug for everyone with your diagnosis. In many cases, clinical guidelines do recommend trying simpler options first. The problem arises when the requirement is applied rigidly, without accounting for individual clinical circumstances — your prior treatment history, your disease severity, and any medical reasons the step drug is inappropriate for you specifically.

Why Insurers Use Step Therapy

The stated rationale is clinical appropriateness: step therapy encourages evidence-based prescribing by ensuring that lower-cost, well-established treatments are tried before expensive alternatives.

The financial rationale is cost containment. Generic and first-tier branded medications cost insurance plans significantly less than specialty drugs, and step therapy delays or prevents some patients from reaching the expensive end of the formulary.

There is also a rebate dimension. Pharmaceutical manufacturers negotiate rebates with pharmacy benefit managers and insurers for formulary placement — the more prescriptions written for a preferred drug, the larger the rebate. Step therapy sequences are sometimes structured in ways that favor rebated products, though demonstrating this causally is difficult given the opacity of rebate agreements. The AMA and patient advocacy organizations have raised this concern in the context of prior authorization reform.

The result is a system where your physician's prescribing decision may conflict with your plan's financial incentives, and the conflict lands on your prescription.

When Step Therapy Is a Clinical Problem

The clinical objection to step therapy is not that first-line drugs are always wrong. It is that requiring a failed trial before access to the right drug is, for some patients, the wrong sequence.

Some conditions respond differently to different drug classes depending on disease subtype, genetic factors, or prior treatment history. Some patients have already tried the required step drug, years earlier, under a different insurer, or in a different clinical context. Some have a documented contraindication to the required drug, a medical reason it cannot safely be prescribed.

In all of these situations, the step therapy requirement as written does not apply accurately to the individual patient. The mechanism for recognizing that fact is the exception process.

How to Get a Step Therapy Exception

Step therapy exceptions are a formal part of the prior authorization appeals process, and they can be requested before, during, or after a denial.

Document prior treatment failure. If you have already tried the required step drug, the exception request must include documentation of that trial: when you took it, at what dose, for how long, and what happened clinically. A prescriber's note that says "patient tried and failed drug X" will be less effective than one that documents specific dates, doses, clinical outcomes, and the reason for discontinuation. Specificity is the argument.

Document a contraindication. If you have a medical reason you cannot safely take the required step drug — a documented allergy, an adverse reaction on record, a comorbid condition that makes it inappropriate — that contraindication can satisfy the exception criteria without requiring a full trial. The documentation must be clinical and specific, not general. An experienced prescriber will know how to frame it.

Cite your state's step therapy reform law. As of 2024, a majority of U.S. states have enacted step therapy reform legislation that defines the circumstances under which insurers must grant exceptions. These laws typically require insurers to grant an exception when a patient has tried and failed the step drug, has a contraindication, or when the required drug is not in the patient's best clinical interest given their specific history. The National Conference of State Legislatures maintains a regularly updated database of state step therapy laws at ncsl.org.

If your state has such a law and your plan is state-regulated, citing the specific statutory provision in your exception request carries legal weight. Self-insured employer plans governed by ERISA are generally exempt from state step therapy laws, which limits their applicability for many commercially insured patients.

Request expedited review when clinically urgent. If your condition is time-sensitive and a standard 14-day review period could cause clinical harm, your prescriber can request expedited review. The plan is required to issue a decision within 72 hours. The prescriber's request must document the clinical urgency specifically.

Gold Carding: When You've Already Proven It Works

Gold carding is a relatively recent development in prior authorization policy, and one that has gained momentum through state legislation.

The concept is straightforward: if a physician has consistently prescribed a drug appropriately over time, or if a patient has been stable on a treatment, the insurer exempts that prescription from future prior authorization requirements. The physician is "gold carded" for that drug and that patient, and the prescription is filled without the standard authorization process.

As of 2024, Texas, Arkansas, West Virginia, and Virginia have enacted gold carding laws that apply to certain commercial plans. Federal legislation on gold carding has been proposed in Congress as part of broader prior authorization reform efforts, though it has not yet passed.

For patients who have been stable on a specialty medication for years and face re-authorization cycles that can cause gaps in therapy, gold carding represents the structural solution — one that removes the recurring administrative barrier rather than addressing it one authorization at a time.

If your state has a gold carding law, your physician may be able to request exemption status, particularly if they have a documented pattern of appropriate prescribing for your medication.

What Your Doctor Needs to Submit

A successful step therapy exception request requires your physician's active involvement. The prescriber must submit documentation that directly addresses the exception criteria the plan applies, not a general letter of advocacy.

That means the letter should explain the clinical basis for the exception — prior treatment failure with specific detail, or a documented contraindication, or a clinical argument tied to disease severity and the medical reason the step drug is inappropriate. If your state's step therapy law specifies the exception criteria, the letter should address those criteria explicitly.

Ellen can help you and your doctor prepare that documentation. Start at ellenrx.com.

The Deadline on Your Right to Appeal

Most prior authorization denials, including those based on step therapy requirements, carry an appeal window. The denial letter will specify the timeframe, and it is typically 30 to 60 days from the date of the denial. Missing that window does not eliminate your right to coverage, but it restarts the process under different procedural rules.

If your prescription was denied because of a step therapy requirement, the appeal window opens at the date on that denial letter. The documentation your physician needs to prepare is what drives the outcome.

Sources: National Conference of State Legislatures, "Step Therapy / Fail First Policies," 2024, ncsl.org; American Medical Association, "2024 Prior Authorization Physician Survey and Policy Report"; AMA, "Prior Authorization Reform Principles and State Law Tracker"; U.S. Department of Labor, "External Claims Review — Your Rights," ACA employee benefits guidance; American College of Rheumatology, "Position Statement on Step Therapy," 2022.